



## Liver Cancer: From Molecular Mechanism to Therapeutic Perspectives

Guest Editors:

**Dr. Tudor Mocan**

Institute of Gastroenterology and Hepatology, "Prof. Dr. Octavian Fodor", University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania

**Dr. Mirosław Kornek**

Department of Internal Medicine I, University Bonn, Venusberg Campus 1, 53127 Bonn, Germany

**Dr. Zeno Spârchez**

Institute of Gastroenterology and Hepatology, "Prof. Dr. Octavian Fodor", University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania

Deadline for manuscript submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

Modern cancer medicine is shifting its perspectives from a “one drug fits all” standpoint to an individualized approach, centered on the analysis of the cellular mechanisms involved in cancer development, such as evaluating the tumor microenvironment, investigating the immune cell composition, or finding new biomarkers. These studies established new molecular targets for different drug therapies which improved overall survival in hepatocellular carcinoma or cholangiocarcinoma; however, liver cancer still remains one of the leading causes of cancer-related deaths worldwide. Undoubtedly, there is a need for a thorough understanding of the mechanisms leading to disease progression and treatment resistance, in order to decrease its global burden. This Special Issues aims to cover both preclinical and clinical studies regarding cellular signaling pathways, experimental models for liver cancer, molecular targets, diagnostic or prognostic biomarkers, and novel therapies. We are confident that our research efforts will provide novel insights into the marked heterogeneity of this type of cancer, while concurrently offer new solutions for precision treatment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)